Author:
Askanase Anca,Khalili Leila,Tang Wei,Mertz Philippe,Scherlinger Marc,Sebbag Eden,Chasset François,Felten Renaud,Arnaud Laurent
Reference54 articles.
1. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus;Riggs;Lupus Sci Med,2018
2. Regulation of type I interferon responses;Ivashkiv;Nat Rev Immunol,2014
3. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial;Furie;The Lancet Rheumatology,2019
4. Trial of anifrolumab in active systemic lupus erythematosus;Morand;N Engl J Med,2020
5. Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus;Furie;Arthritis Rheumatol,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献